Older pharmacologic therapy for nocturnal enuresis

Area of Science:

• Pediatric Nephrology
• Pediatric Urology
• Clinical Pharmacology

Background:

• Childhood enuresis (bedwetting) has been managed with various pharmacologic agents since the 1960s.
• Established treatments include tricyclic antidepressants, anticholinergics, and desmopressin acetate.
• Certain agents like sedatives and stimulants have shown no benefit.

Purpose of the Study:

• To review the efficacy and application of pharmacologic treatments for childhood enuresis.
• To highlight the importance of patient evaluation prior to drug therapy.
• To compare the effectiveness and side effect profiles of key medications.

Main Methods:

• Literature review of pharmacologic agents used for childhood enuresis.
• Analysis of treatment outcomes for imipramine, oxybutynin, and desmopressin acetate (DDAVP).
• Evaluation of medication suitability based on patient-specific conditions.

Main Results:

• Imipramine (a tricyclic antidepressant) has extensive research and usage history.
• Oxybutynin is effective for enuresis associated with small bladder capacity and daytime symptoms.
• Desmopressin acetate (DDAVP) demonstrates comparable response rates to imipramine with a better side effect profile.

Conclusions:

• Pharmacologic interventions are valuable in treating childhood enuresis, even in cases with underlying organic issues.
• Imipramine, oxybutynin, and DDAVP represent key treatment options with distinct indications.
• DDAVP offers a favorable alternative to imipramine due to its reduced side effects.